You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
醫美板塊全線反彈 華熙生物、愛博醫療雙雙漲超7%
格隆匯6月21日丨醫美板塊全線反彈,愛博醫療、華熙生物雙雙漲超7%,昊海生科、愛美客漲超6%,朗姿股份、金髮拉比、貝泰妮、華東醫藥等跟漲。6月10日,國家衞健委等部門印發《打擊非法醫療美容服務專項整治工作方案》,將於6月到12月聯合開展打擊非法醫療美容服務專項整治工作。受此影響,醫美概念股持續調整。儘管監管開始對醫美行業進行新一輪規範監管,但在行業看來,這個市場仍具有較大的增長空間。從阿里健康獲悉,618期間,天貓醫藥平台上和“變美”“調節身體機能”相關的健康商品成為最受歡迎的趨勢商品。監管趨嚴,行業不斷規範,進而保護消費者,減少行業負面事件以維護行業整體形象,能推動醫美產業長足健康發展。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.